ICPT - Intercept Pharmaceuticals, Inc.
After hours:
Chart Events
Inside Bar (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 11.12 |
| Open | 11.05 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 10.97 - 11.40 |
| 52 Week Range | 8.82 - 21.86 |
| Volume | |
| Avg. Volume | 1,156,737 |
| Market Cap | 466.479M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.08 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.92 |
Fair Value
Related Research
Simply Wall St.Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Shift From Loss To Profit
We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s ( NASDAQ:ICPT ) business as it appears...
GlobeNewswireIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
MORRISTOWN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Jefferies Healthcare Conference at the Marriott Marquis in New York City on June 7-8, 2023. Meeting Details For investors attending the conference who wish to meet with the Intercep
ZacksBiotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.
Motley FoolWhy Madrigal Pharmaceuticals Stock Is Marching Higher Today
Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key tailwinds. First, a Food and Drug Administration (FDA) panel voted overwhelmingly last Friday against approving Intercept Pharmaceuticals' (NASDAQ: ICPT) candidate, obeticholic acid, for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
- Investing.com
4 big analyst cuts: Apple loses buy rating on slack iPhone demand
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Loop Capital downgraded Apple (NASDAQ:AAPL) to Hold from Buy with a price target of $180.00. The firm sees a material downside risk to revenue (both iPhone and overall) estimates for Q3, relative to both the company’s guidance and Street forecasts.
Investor's Business DailyIntercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug
The FDA will likely reject Intercept Pharmaceuticals' highly watched liver disease treatment, analysts said Monday as ICPT stock crashed.
Barrons.comNASH Drugs Suffer Another Blow, but Hope Remains
Intercept's obeticholic acid may not lead a pack of drugs to treat the liver condition known as nonalcoholic steatohepatitis, or NASH, but other candidates remain.
ZacksIntercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
BenzingaIntercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its Dreams To Enter NASH Space
FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 fibrosis. Fifteen of 16 voting-eligible GIDAC members (with no abstentions) voted to defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional a
- GlobeNewswire
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?” 15 of 16 voting-eligible advisors vote to “defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered” PDUFA Target Action Date set for June 22, 2023 Company to host conference call
- Reuters
UPDATE 3-US FDA panel votes against approval of Intercept fatty liver drug, cites safety issues
The panel of outside experts voted 15-to-1 against the approval for obeticholic acid (OCA) based on surrogate biomarker data suggesting it was likely to benefit patients with NASH (non-alcoholic steatohepatitis) and fibrosis, or scarring, of the liver. The panel by a wide 12-to-2 margin voted that the benefits of Intercept's drug did not outweigh the risks in NASH patients with fibrosis based on current data. Responding to the FDA decision Intercept CEO Jerry Durso said in a statement, "We are disappointed in the outcome of today’s meeting."
- Reuters
US FDA panel votes against accelerated approval of Intercept fatty liver drug
A panel of advisers to the U.S. Food and Drug Administration on Friday recommended holding off on an accelerated approval of Intercept Pharmaceuticals Inc's oral drug for a type of fatty liver disease until more study data is available. The panel of outside experts voted 15-to-1 against the approval for obeticholic acid (OCA) based on surrogate biomarker data suggesting it was likely to benefit patients with NASH (non-alcoholic steatohepatitis) and fibrosis, or scarring, of the liver.
- GlobeNewswire
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) is meeting today to review obeticholic acid (OCA) as a treatment for pre-cirrhoti
ZacksIntercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
- Investing.com
4 big analyst cuts: Nu slashed at Citi, Futu gets 2 downgrades
Here is your Pro Recap of the biggest analyst cut you may have missed since yesterday: downgrades for Nu, Futu, Magellan Midstream, and Intercept Pharmaceuticals. Citi downgraded digital banking platform Nu (NYSE:NU) to Neutral from Buy and cut its price target to $6.10 from $7.00, as reported in real time on InvestingPro. Futu (NASDAQ:FUTU) shares fell around 2% pre-market today after the company received downgrades from JPMorgan and Morgan Stanley following the announcement that the company is removing its app from China’s onshore app stores.
BenzingaWhy Intercept Pharmaceuticals Shares Are Plunging Today
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around 20% after the FDA issued briefing documents ahead of the adcomm meeting scheduled for May 19 to review its liver disease candidate Obeticholic Acid (OCA). PDUFA Target Action Date set for June 22, 2023. The FDA briefing document highlighted an increased risk of diabetes and liver injury from using the obeticholic acid (OCA) oral tablets to treat nonalcoholic steatohepatitis (NASH). In the briefing documents, the FDA reviewers raised concer
ZacksIntercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
- Reuters
US FDA staff flag liver damage concerns about Intercept's NASH treatment
The U.S. health regulator's staff reviewers on Wednesday raised concerns about potential liver damage from using Intercept Pharmaceuticals Inc's oral tablets for treatment of a type of fatty liver disease, sending the company's shares 20% lower in premarket trade. A panel of outside advisors to the U.S. Food and Drug Administration (FDA) are set to meet on Friday to discuss the marketing application for obeticholic acid oral tablets, making it the first advisory committee meeting for a drug to treat nonalcoholic steatohepatitis (NASH).
- GlobeNewswire
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023 Results from planned interim analysis of Phase 2 study evaluating the effects of OCA and bezafibrate on serum biomarkers in PBC to be presented at EASL Congress 2023 MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to tre
ZacksIntercept (ICPT) Gains 26.2% YTD: What's in Store?
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
InvestopediaTop Healthcare Stocks for May 2023
Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum.
- Simply Wall St.
Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Low P/S No Reason For Excitement
With a price-to-sales (or "P/S") ratio of 2.3x Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) may be sending very...
Motley FoolWhy Intercept Pharmaceuticals Stock Plunged Today
Shares of the non-viral liver disease specialist Intercept Pharmaceuticals (NASDAQ: ICPT) are under heavy pressure today. The big loss came in response to weaker-than-expected 2023 first-quarter sales of Intercept's primary biliary cholangitis (PBC) therapy, Ocaliva (obeticholic acid). This relatively modest revenue miss probably isn't the reason Intercept's shares are falling today.
ZacksIntercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of -35.09% and 7.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting set for May 19, 2023, to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH; PDUFA Target Action Date set for June 22, 2023 Company updates progress of OCA-bezafibrate fixed-dose combination development program in PBC, including acceptance of new Phase 2 data at EASL Congress 2023 Company to host conference call today